undamentalytics Newsletter
Sign in

Cormedix Inc. cash flow statement

In fiscal 2025, Cormedix Inc.'s operations generated $175m of cash; it spent $2.3m on capital projects, leaving free cash flow of $173m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−2−4−6−13−22−29−24−15−22−21−24−51175254
Depreciation and amortisation000000000000121
Stock-based pay0123121225461416
Capital spending00000000010024
Free cash flow−2−4−6−13−22−29−24−15−22−23−25−51173250
Free cash flow after stock pay−3−5−9−16−24−30−25−18−25−28−29−57159234
Shares issued00028000151841181981

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ARQT vs CRMDCRMD vs KRYSARDX vs CRMD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cormedix Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cormedix Inc.